Analyst Ratings For GlaxoSmithKline (LON:GSK)
Today, Shore Capital reiterated its Hold rating on GlaxoSmithKline (LON:GSK).
There are 11 Hold Ratings, 5 Buy Ratings, 2 Sell Ratings, no Strong Buy Ratings on the stock.
The current consensus rating on GlaxoSmithKline (LON:GSK) is Hold with a consensus target price of GBX 1,518.15 per share, a potential .
Some recent analyst ratings include
- 3/20/2019-GlaxoSmithKline (LON:GSK) had its Hold rating reiterated by Shore Capital
- 3/20/2019-GlaxoSmithKline (LON:GSK) had its Hold rating reiterated by Liberum Capital
- 3/19/2019-GlaxoSmithKline (LON:GSK) had its Neutral rating reiterated by UBS Group
- 3/14/2019-GlaxoSmithKline (LON:GSK) had its Buy rating reiterated by Jefferies Financial Group
- 3/11/2019-GlaxoSmithKline (LON:GSK) had its Equal weight rating reiterated by Barclays
About GlaxoSmithKline (LON:GSK)
GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of vaccines, over-the-counter medicines, and health-related consumer products worldwide. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, dermatology, rare diseases, immuno-inflammation, and HIV, as well as vaccines. It also provides consumer healthcare products in wellness, oral health, nutrition, and skin health categories primarily under the Otrivin, Panadol, Fenistil, Lamisil, Breathe Right, Stiefel, Excedrin, Physiogel, Polident, parodontax, Poligrip, Sensodyne, Theraflu, and Voltaren brand names. The company offers its consumer healthcare products in the form of tablets, caplets, infant syrup drops, syrups, topical gels, nasal sprays, effervescents, lozenges, gum and trans-dermal patches, malted drinks and foods, and topical creams and non-medicated patches, as well as toothpastes, toothbrushes, mouth rinses, medicated mouthwashes, gels and sprays, denture adhesives, and denture cleansers. It has a discovery collaboration agreement with Kymera Therapeutics LLC; a collaboration agreement with InSysBio LLC to develop quantitative systems pharmacology model of asthma; a strategic collaboration with NeuroMetrix, Inc. to develop and market Quell technology; and strategic alliance with Merck KGaA to jointly develop and commercialize M7824 (bintrafusp alfa), an investigational bifunctional fusion protein immunotherapy. GlaxoSmithKline plc also has a joint research collaboration with Fimbrion Therapeutics Inc. to develop a small molecule candidate for the treatment and prevention of urinary tract infections. The company was founded in 1715 and is headquartered in Brentford, the United Kingdom.
Recent Trading Activity for GlaxoSmithKline (LON:GSK)
Shares of GlaxoSmithKline closed the previous trading session at 528,40 up +25,20 1,68 % with 40.76 shares trading hands.